Adam E Haynes

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary
    Donna E Maziak
    University of Ottawa, Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ont, Canada K1H 8L6
    Lung Cancer 48:157-69. 2005
  2. ncbi The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline
    Peter Ellis
    McMaster University at Hamilton Health Sciences and Juravinski Cancer Centre, Hamilton, Ontario, Canada
    J Thorac Oncol 1:591-601. 2006
  3. ncbi The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review
    Yee C Ung
    Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
    Brachytherapy 5:189-202. 2006
  4. ncbi The role of radiation therapy in malignant pleural mesothelioma: a systematic review
    Yee C Ung
    Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
    Radiother Oncol 80:13-8. 2006
  5. ncbi Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma
    Shailendra Verma
    Division of Medical Oncology, Ottawa Hospital, 501 Smyth Road, Ottawa, Canada K1H 8L6
    Cancer Treat Rev 34:339-47. 2008
  6. ncbi Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review
    Shailendra Verma
    Ottawa Hospital, Ottawa, Ontario, Canada
    Cancer 112:1197-205. 2008
  7. ncbi Yttrium 90 ibritumomab tiuxetan in lymphoma
    Matthew C Cheung
    Cancer Care Ontario, Program in Evidence-based Care, McMaster University, Hamilton, Ontario, Canada
    Leuk Lymphoma 47:967-77. 2006
  8. ncbi Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario
    Matthew C Cheung
    Cancer Care Ontario Program in Evidence Based Care, McMaster University, Hamilton, Ont, Canada L8S 4L8
    Cancer Treat Rev 33:161-76. 2007
  9. ncbi Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review
    Teresa Petrella
    Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    Cancer Treat Rev 33:484-96. 2007
  10. ncbi The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review
    Nadine Shehata
    Department of Medicine, St Michael s Hospital, University of Toronto, Canadian Blood Services, Toronto, Canada
    Ann Hematol 87:961-73. 2008

Collaborators

Detail Information

Publications10

  1. ncbi Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary
    Donna E Maziak
    University of Ottawa, Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ont, Canada K1H 8L6
    Lung Cancer 48:157-69. 2005
    ..Future studies of the role of surgery in the treatment of mesothelioma should include evaluations of quality of life...
  2. ncbi The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline
    Peter Ellis
    McMaster University at Hamilton Health Sciences and Juravinski Cancer Centre, Hamilton, Ontario, Canada
    J Thorac Oncol 1:591-601. 2006
    ....
  3. ncbi The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review
    Yee C Ung
    Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
    Brachytherapy 5:189-202. 2006
    ..This review addresses the role of high-dose-rate endobronchial brachytherapy (HDREB) for symptom palliation in patients with non-small-cell lung cancer...
  4. ncbi The role of radiation therapy in malignant pleural mesothelioma: a systematic review
    Yee C Ung
    Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
    Radiother Oncol 80:13-8. 2006
    ..Radiation therapy may offer patients presenting with malignant pleural mesothelioma (MPM) symptom palliation and improvements in quality of life. This systematic review will address the role of radiation therapy in the management of MPM...
  5. ncbi Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma
    Shailendra Verma
    Division of Medical Oncology, Ottawa Hospital, 501 Smyth Road, Ottawa, Canada K1H 8L6
    Cancer Treat Rev 34:339-47. 2008
    ..This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma. Outcomes of interest include overall survival, response rate, adverse effects, and quality of life...
  6. ncbi Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review
    Shailendra Verma
    Ottawa Hospital, Ottawa, Ontario, Canada
    Cancer 112:1197-205. 2008
    ....
  7. ncbi Yttrium 90 ibritumomab tiuxetan in lymphoma
    Matthew C Cheung
    Cancer Care Ontario, Program in Evidence-based Care, McMaster University, Hamilton, Ontario, Canada
    Leuk Lymphoma 47:967-77. 2006
    ..90Y-ibritumomab tiuxetan is an active agent in relapsed and refractory non-Hodgkin's lymphoma that should be considered in select patients...
  8. ncbi Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario
    Matthew C Cheung
    Cancer Care Ontario Program in Evidence Based Care, McMaster University, Hamilton, Ont, Canada L8S 4L8
    Cancer Treat Rev 33:161-76. 2007
    ..The consensus opinion of the Hematology Disease Site Group is that rituximab is recommended for these indications...
  9. ncbi Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review
    Teresa Petrella
    Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    Cancer Treat Rev 33:484-96. 2007
    ..Outcomes of interest include objective and complete response rates, duration of response, toxicity and quality of life...
  10. ncbi The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review
    Nadine Shehata
    Department of Medicine, St Michael s Hospital, University of Toronto, Canadian Blood Services, Toronto, Canada
    Ann Hematol 87:961-73. 2008
    ..Limitations of these data preclude conclusions that these agents improve QOL. More data are required to confirm the inferior survival associated with ESAs...